

Daniel J Donoghue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4572040/publications.pdf>

Version: 2024-02-01

21
papers

525
citations

759233

12
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. <i>Acta Neuropathologica Communications</i> , 2022, 10, 65.	5.2	8
2	Proteomic analysis reveals dual requirement for Grb2 and PLC β 1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation. <i>Oncotarget</i> , 2022, 13, 659-676.	1.8	4
3	Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. <i>Oncotarget</i> , 2021, 12, 22-36.	1.8	9
4	Typical achondroplasia secondary to a unique insertional variant of <i>FGFR3</i> with in vitro demonstration of its effect on <i>FGFR3</i> function. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 798-805.	1.2	4
5	Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. <i>Haematologica</i> , 2020, 105, 1262-1273.	3.5	20
6	Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. <i>Cytokine and Growth Factor Reviews</i> , 2020, 52, 56-67.	7.2	44
7	Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors. <i>Translational Oncology</i> , 2020, 13, 100853.	3.7	3
8	Characterization of iPS87, a prostate cancer stem cell-like cell line. <i>Oncotarget</i> , 2020, 11, 1075-1084.	1.8	5
9	BCR: a promiscuous fusion partner in hematopoietic disorders. <i>Oncotarget</i> , 2019, 10, 2738-2754.	1.8	22
10	Oncogenic mutations in IKK β function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation. <i>PLoS ONE</i> , 2018, 13, e0206014.	2.5	3
11	Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. <i>Oncotarget</i> , 2018, 9, 34306-34319.	1.8	24
12	Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders. <i>Trends in Molecular Medicine</i> , 2017, 23, 59-79.	6.7	29
13	Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation. <i>Molecular Cancer Research</i> , 2016, 14, 458-469.	3.4	69
14	Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 425-449.	7.2	125
15	Novel Lys63-linked ubiquitination of IKK β induces STAT3 signaling. <i>Cell Cycle</i> , 2014, 13, 3964-3976.	2.6	20
16	Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGF β -Activated Kinase 1 Tyrosine Phosphorylation and NF κ B Signaling in Multiple Myeloma and Bladder Cancer. <i>PLoS ONE</i> , 2014, 9, e86470.	2.5	27
17	Early Human Prostate Adenocarcinomas Harbor Androgen-Independent Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e74438.	2.5	26
18	Tyrosine Phosphorylation Allows Integration of Multiple Signaling Inputs by IKK β . <i>PLoS ONE</i> , 2013, 8, e84497.	2.5	4

#	ARTICLE	IF	CITATIONS
19	The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling. PLoS ONE, 2010, 5, e14412.	2.5	51
20	The atypical CDK activator Spy1 regulates the intrinsic DNA damage response and is dependent upon p53 to inhibit apoptosis. Cell Cycle, 2009, 8, 66-75.	2.6	28
21	Constitutively Activated FGFR3 Mutants Signal through PLC β - Dependent and -Independent Pathways for Hematopoietic Transformation.. Blood, 2004, 104, 1423-1423.	1.4	0